Intravenous and subcutaneous desferrioxa
β
G. E. Janka; P. MΓΆhring; M. Helmig; R. J. Haas; K. Betke
π
Article
π
1981
π
Springer
π
English
β 430 KB
Ten children with transfusion dependent anemias (thalassemia, sideroblastic anemia, congenital pure red cell aplasia) received either intravenous desferrioxamine (DF) in increasing doses up to 450 mg/kg at the time of transfusion or daily subcutaneous DF up to ll0mg/kg on an outpatient basis. No pat